IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Brentuximab Vedotin
The First Affiliated Hospital with Nanjing Medical Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the Brentuximab Vedotin cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
Inno-206 The First Affiliated Hospital with Nanjing Medical University | Phase 2/3 | B |
PREDNISONE TABLETS The First Affiliated Hospital with Nanjing Medical University | Phase 2/3 | B |
Cyclophosphamide The First Affiliated Hospital with Nanjing Medical University | Phase 2/3 | B |
Tislelizumab Children's Cancer Group, China | Phase 2/3 | CCC |
ETOPOSIDE Children's Cancer Group, China | Phase 2/3 | CCC |
DACARBAZINE Children's Cancer Group, China | Phase 2/3 | CCC |
Bedamustine Children's Cancer Group, China | Phase 2/3 | CCC |
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →